News Novo Nordisk's CagriSema data disappoints investors again Novo Nordisk's obesity candidate CagriSema has underwhelmed in a second phase 3 trial, sending the company's share into a sharp decline.
News Lilly uses Oscars ad to warn about 'untested' GLP-1s Eli Lilly has used an Oscars ad to urge people not to use unapproved and untested weight-loss medicines in a swipe at the compounding sector.
News Lilly unveils $27bn reshoring drive around four new plants Trump threatened tariffs if businesses do not reshore production to the US - and Lilly has now revealed a $27bn spend on new domestic facilities.
News Data cues up AZ oral SERD filing in first-line breast cancer AstraZeneca could be the first to bring an oral SERD to market in first-line breast cancer after camizestrant hit the mark in a phase 3 trial.
News Lilly launches discounted high-strength Zepbound vials in US Eli Lilly's drive to provide as many treatment options as possible for its obesity drug Zepbound has continued with the launch of new high-dose vials.
News Evidence builds behind Regeneron's deafness gene therapy Ten out of 11 children with congenital deafness treated with a gene therapy developed by Regeneron have seen "notable" improvements in hearing.
News MIT team develops 'years-long' drug delivery tech Researchers in the US have devised a new depot system that could provide months or even years of delivery from a single subcutaneous injection.
Sales & Marketing Sponsored Health Trends 2025: Reimagining What's Possible Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl